Evaluation of Side Effects of Mitotane
Active, not recruiting
- Conditions
- Adrenocortical Carcinoma
- Registration Number
- NCT00568139
- Lead Sponsor
- University of Wuerzburg
- Brief Summary
Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many adverse effects are not well documented. Therefore, we are aiming at collecting data about adverse effects in patients treated with mitotane
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
- Adrenocortical carcinoma
- Treatment with mitotane monotherapy as first-line therapy (in adjuvant setting or advanced disease)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Documentation of adverse effects from starting mitotane until discontinuation of mitotane (since this is very variable from patient to patient no specific number of days or weeks can be entered (standard therapy would be about 2 years) or start of additional other medical therapies Adverse effects will be documented using the NCI CTC AE v5.5
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital
🇩🇪Wuerzburg, Germany